Microbial Translocation Is Associated with Extensive Immune Activation in Dengue Virus Infected Patients with Severe Disease

Carregando...
Imagem de Miniatura
Citações na Scopus
66
Tipo de produção
article
Data de publicação
2013
Editora
PUBLIC LIBRARY SCIENCE
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
WEG, Cornelia A. M. van de
ARAUJO, Evaldo S. A. de
HAM, Henk-Jan van den
ANDEWEG, Arno C.
FELIX, Alvina C.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
PLOS NEGLECTED TROPICAL DISEASES, v.7, n.5, article ID e2236, 13p, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Severe dengue virus (DENV) disease is associated with extensive immune activation, characterized by a cytokine storm. Previously, elevated lipopolysaccharide (LPS) levels in dengue were found to correlate with clinical disease severity. In the present cross-sectional study we identified markers of microbial translocation and immune activation, which are associated with severe manifestations of DENV infection. Methods: Serum samples from DENV-infected patients were collected during the outbreak in 2010 in the State of Sao Paulo, Brazil. Levels of LPS, lipopolysaccharide binding protein (LBP), soluble CD14 (sCD14) and IgM and IgG endotoxin core antibodies were determined by ELISA. Thirty cytokines were quantified using a multiplex luminex system. Patients were classified according to the 2009 WHO classification and the occurrence of plasma leakage/shock and hemorrhage. Moreover, a (non-supervised) cluster analysis based on the expression of the quantified cytokines was applied to identify groups of patients with similar cytokine profiles. Markers of microbial translocation were linked to groups with similar clinical disease severity and clusters with similar cytokine profiles. Results: Cluster analysis indicated that LPS levels were significantly increased in patients with a profound pro-inflammatory cytokine profile. LBP and sCD14 showed significantly increased levels in patients with severe disease in the clinical classification and in patients with severe inflammation in the cluster analysis. With both the clinical classification and the cluster analysis, levels of IL-6, IL-8, sIL-2R, MCP-1, RANTES, HGF, G-CSF and EGF were associated with severe disease. Conclusions: The present study provides evidence that both microbial translocation and extensive immune activation occur during severe DENV infection and may play an important role in the pathogenesis.
Palavras-chave
Referências
  1. Azeredo EL, 2001, IMMUNOBIOLOGY, V204, P494, DOI 10.1078/0171-2985-00058
  2. Bethell DB, 1998, J INFECT DIS, V177, P778
  3. Bosisio D, 2002, BLOOD, V99, P3427, DOI 10.1182/blood.V99.9.3427
  4. Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86
  5. Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511
  6. Bukh AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021275
  7. CARUSO C, 1993, MEDIAT INFLAMM, V2, P3, DOI 10.1155/S0962935193000018
  8. Chen JP, 2006, J IMMUNOL, V177, P3185
  9. Chen YC, 1999, J VIROL, V73, P2650
  10. Chen YC, 2002, J VIROL, V76, P9877, DOI 10.1128/JVI.76.19.9877-9887.2002
  11. Crisostomo PR, 2008, AM J PHYSIOL-CELL PH, V294, pC675, DOI 10.1152/ajpcell.00437.2007
  12. de Souza VAUF, 2004, J CLIN MICROBIOL, V42, P1782, DOI 10.1128/JCM.42.4.1782-1784.2004
  13. Felix AC, 2012, CLIN VACCINE IMMUNOL, V19, P1972, DOI 10.1128/CVI.00535-12
  14. Green S, 1999, J INFECT DIS, V179, P755, DOI 10.1086/314680
  15. Green S, 1999, J MED VIROL, V59, P329, DOI 10.1002/(SICI)1096-9071(199911)59:3<329::AID-JMV12>3.3.CO;2-7
  16. Halstead SB, 2003, ADV VIRUS RES, V60, P421, DOI 10.1016/S0065-3527(03)60011-4
  17. Harris E, 1998, J CLIN MICROBIOL, V36, P2634
  18. HOBER D, 1993, AM J TROP MED HYG, V48, P324
  19. Hofer U, 2009, SEMIN IMMUNOPATHOL, V31, P257, DOI 10.1007/s00281-009-0158-3
  20. John CC, 2006, J INFECT DIS, V194, P837, DOI 10.1086/506623
  21. KURANE I, 1991, J CLIN INVEST, V88, P1473, DOI 10.1172/JCI115457
  22. LANDMANN R, 1995, J INFECT DIS, V171, P639
  23. Lee YR, 2006, J GEN VIROL, V87, P3623, DOI 10.1099/vir.0.82093-0
  24. Libraty DH, 2002, J INFECT DIS, V185, P1213, DOI 10.1086/340365
  25. Martina BEE, 2009, CLIN MICROBIOL REV, V22, P564, DOI 10.1128/CMR.00035-09
  26. Murphy KP, 2008, JANEWAYS IMMUNOBIOLO
  27. Nguyen Thanh Hung, 2004, Journal of Infectious Diseases, V189, P221
  28. Opal SM, 1999, J INFECT DIS, V180, P1584, DOI 10.1086/315093
  29. Pacsa AS, 2000, FEMS IMMUNOL MED MIC, V28, P151, DOI 10.1016/S0928-8244(00)00147-4
  30. Perez AB, 2004, J MED VIROL, V73, P230, DOI 10.1002/jmv.20080
  31. Redd AD, 2009, P NATL ACAD SCI USA, V106, P6718, DOI 10.1073/pnas.0901983106
  32. Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011811
  33. Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014
  34. Santos-Oliveira JR, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001198
  35. Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711
  36. Sierra B, 2010, CYTOKINE, V52, P175, DOI 10.1016/j.cyto.2010.06.010
  37. Srikiatkhachorn A, 2007, J VIROL, V81, P1592, DOI 10.1128/JVI.01642-06
  38. Suharti C, 2003, EUR CYTOKINE NETW, V14, P172
  39. Tang YB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015631
  40. Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
  41. van den Ham HJ, 2009, RHEUMATOLOGY, V48, P899, DOI 10.1093/rheumatology/kep125
  42. van de Weg CAM, 2012, AM J TROP MED HYG, V86, P166, DOI 10.4269/ajtmh.2012.11-0491
  43. van de Weg CAM, 2012, J CLIN VIROL, V53, P38, DOI 10.1016/j.jcv.2011.09.028
  44. Wang WM, 2011, INFLAMMATION, V34, P509, DOI 10.1007/s10753-010-9258-4
  45. World Health Organization, 2009, DENG HEM FEV DIAGN T